75 related articles for article (PubMed ID: 21624559)
1. Guest Editorial: new PET radiopharmaceuticals as molecular imaging probes.
Vallabhajosula S
Semin Nucl Med; 2011 Jul; 41(4):244-5. PubMed ID: 21624559
[No Abstract] [Full Text] [Related]
2. Developing new molecular imaging probes for PET.
Serdons K; Verbruggen A; Bormans GM
Methods; 2009 Jun; 48(2):104-11. PubMed ID: 19318126
[TBL] [Abstract][Full Text] [Related]
3. Target-specific delivery of peptide-based probes for PET imaging.
Chen K; Conti PS
Adv Drug Deliv Rev; 2010 Aug; 62(11):1005-22. PubMed ID: 20851156
[TBL] [Abstract][Full Text] [Related]
4. Molecular tracers for the PET and SPECT imaging of disease.
Pimlott SL; Sutherland A
Chem Soc Rev; 2011 Jan; 40(1):149-62. PubMed ID: 20818455
[TBL] [Abstract][Full Text] [Related]
5. Radiopharmaceuticals: molecular imaging using positron emission tomography.
Antoni G; Långström B
Handb Exp Pharmacol; 2008; (185 Pt 1):177-201. PubMed ID: 18626804
[TBL] [Abstract][Full Text] [Related]
6. Molecular imaging targeting peptide receptors.
Schottelius M; Wester HJ
Methods; 2009 Jun; 48(2):161-77. PubMed ID: 19324088
[TBL] [Abstract][Full Text] [Related]
7. Radiopharmaceutical chemistry for positron emission tomography.
Li Z; Conti PS
Adv Drug Deliv Rev; 2010 Aug; 62(11):1031-51. PubMed ID: 20854860
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET CT for tumor imaging.
Miller JC; Fischman AJ; Aquino SL; Blake MA; Thrall JH; Lee SI
J Am Coll Radiol; 2007 Apr; 4(4):256-9. PubMed ID: 17412280
[No Abstract] [Full Text] [Related]
9. The Medical Imaging & Technology Alliance conference on research endpoints appropriate for medicare coverage of new PET radiopharmaceuticals.
Hillman BJ; Frank RA; Abraham BC
J Am Coll Radiol; 2013 Sep; 10(9):689-94. PubMed ID: 23916799
[TBL] [Abstract][Full Text] [Related]
10. Current use of 18F-fluorodeoxyglucose positron emission tomography and combined positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck.
Zimmer LA; Branstetter BF; Nayak JV; Johnson JT
Laryngoscope; 2005 Nov; 115(11):2029-34. PubMed ID: 16319618
[TBL] [Abstract][Full Text] [Related]
11. Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma.
Quon A; Fischbein NJ; McDougall IR; Le QT; Loo BW; Pinto H; Kaplan MJ
J Nucl Med; 2007 Jan; 48 Suppl 1():58S-67S. PubMed ID: 17204721
[TBL] [Abstract][Full Text] [Related]
12. What is now current good manufacturing practice for PET drugs?
Harolds J
Clin Nucl Med; 2010 May; 35(5):329. PubMed ID: 20395704
[TBL] [Abstract][Full Text] [Related]
13. Small animal PET in preclinical studies: opportunities and challenges.
Riemann B; Schäfers KP; Schober O; Schäfers M
Q J Nucl Med Mol Imaging; 2008 Sep; 52(3):215-21. PubMed ID: 18551093
[TBL] [Abstract][Full Text] [Related]
14. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
[TBL] [Abstract][Full Text] [Related]
15. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
16. Operational radiation safety for PET-CT, SPECT-CT, and cyclotron facilities.
Zanzonico P; Dauer L; St Germain J
Health Phys; 2008 Nov; 95(5):554-70. PubMed ID: 18849690
[TBL] [Abstract][Full Text] [Related]
17. Methodological aspects of multicenter studies with quantitative PET.
Boellaard R
Methods Mol Biol; 2011; 727():335-49. PubMed ID: 21331942
[TBL] [Abstract][Full Text] [Related]
18. Improving PET Evaluation of Brain Tumors.
Cancer Discov; 2015 May; 5(5):458-9. PubMed ID: 25808525
[No Abstract] [Full Text] [Related]
19. Microfluidics: a golden opportunity for positron emission tomography?
Fortt R; Gee A
Future Med Chem; 2013 Mar; 5(3):241-4. PubMed ID: 23464514
[No Abstract] [Full Text] [Related]
20. Updates to the Appropriate-Use Criteria for Somatostatin Receptor PET.
Hope TA
J Nucl Med; 2020 Dec; 61(12):1764. PubMed ID: 33262268
[No Abstract] [Full Text] [Related]
[Next] [New Search]
